Download PDF

1. Company Snapshot

1.a. Company Description

Cerus Corporation operates as a biomedical products company.The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.


The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced.It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally.The company was incorporated in 1991 and is headquartered in Concord, California.

Show Full description

1.b. Last Insights on CERS

Cerus Corporation's recent performance was negatively impacted by the lack of recent earnings releases, with the last update being the Q4 2024 earnings call on February 20, 2025. The absence of recent financial results and management's outlook may have contributed to investor uncertainty. Additionally, the company's focus on regulatory approvals, such as the CE mark approval for its next-generation INTERCEPT Illumination Device (INT200) on March 5, 2025, may not have been enough to offset the lack of recent financial updates.

1.c. Company Highlights

2. Cerus Corporation's 2025 Earnings: A Year of Progress and Growth

Cerus Corporation reported total revenues of $233.8 million for 2025, representing a 16% increase from 2024, with product revenue reaching a record $224 million to $228 million, up 14% for both the quarter and the year. The company's GAAP net loss attributable to Cerus was $15.6 million for the full year, down 25% from the prior year. The actual EPS came in at '-0.01', in line with estimates. Non-GAAP adjusted EBITDA was $9.5 million for the full year, indicating the company's efforts to improve its profitability. The revenue growth was driven by a 25% increase in EMEA product revenue in the fourth quarter and 14% for the full year, as well as an 80% growth in IFC product revenue for the full year.

Publication Date: Mar -08

📋 Highlights
  • Revenue Growth & Market Expansion: Total revenues rose to $233.8M (+16% YoY), with product revenue hitting $224M–$228M (+14% YoY); EMEA revenue grew 25% Q4 and 14% YoY, driven by INT200 adoption and plasma/platelet demand.
  • INTERCEPT Adoption Progress: Blood centers produced ~3M treated components in 2025, benefiting 600K patients; IFC revenue surged 40% Q4 and 80% YoY, with market penetration at ~7% by end-2025, targeting >50% growth by year-end.
  • BCA Partnership Impact: Signed contract with Blood Centers of America (BCA) to boost INTERCEPT adoption; BCA represents 50% of US platelet market, with Cerus currently at ~30% penetration, aiming to leverage BCA’s supply chain and contracting.
  • Financial Performance & Outlook: GAAP net loss narrowed to $15.6M (-25% YoY); non-GAAP EBITDA reached $9.5M; 2026 product revenue guidance of $224M–$228M (+9%–11% YoY), with IFC revenue expected to grow 20%–30% YoY.
  • Regulatory & Development Milestones: INT200 launched with CE Mark; TÜV-SÜD review completed for red blood cell approval, with CE Mark submission to ANSM pending; Phase III RedeS study in the US and Phase IV INITIATE study in Germany (targeting $30M annual platelet opportunity) on track for 2026 readouts.

Regional Performance and Drivers

The company's regional performance was notable, with EMEA reporting 36% growth in Q4, driven by strength in the Middle East, particularly in the Kingdom of Saudi Arabia. The company is pursuing a $30 million annual opportunity in platelets in Germany, where a Phase IV post-market study, INITIATE, is ongoing and expected to read out in 2026. In the US, the Phase III RedeS study for red blood cells has completed enrollment and is expected to read out in Q4 2026. As CFO, William M. Greenman, noted, the BCA contract is expected to drive penetration of INTERCEPT beyond current levels, particularly in the US platelet market.

Operational Highlights and Future Expectations

Cerus exited 2025 with IFC market adoption at around 7% and expects its penetration rate to increase by more than 50% by the end of the year. The company expects to continue delivering leverage in the P&L, with operating expenses increasing 7% and 10% for the fourth quarter and full year, respectively. For 2026, the company expects product revenue of $224 million to $228 million, representing a year-over-year increase of 9% to 11%. Analysts estimate next year's revenue growth at 8.6%, indicating a consistent upward trend.

Valuation and Outlook

With a P/S Ratio of 1.8 and an EV/EBITDA of -59.19, the market seems to be pricing in a challenging path to profitability. However, the company's efforts to expand its patient access and advance its pipeline, coupled with the expected growth in revenue, may positively impact its valuation. The Free Cash Flow Yield of 2.3% suggests that the company is generating cash, which it plans to invest in inventory to meet anticipated growth. Overall, Cerus Corporation's 2025 earnings report demonstrates the company's progress in establishing INTERCEPT as the global standard of care for transfused blood components, with a promising outlook for 2026 and beyond.

3. NewsRoom

Card image cap

Kevin Dennis Green Sells 127,544 Shares of Cerus (NASDAQ:CERS) Stock

Mar -18

Source: defenseworld.net

Card image cap

Vivek Jayaraman Sells 165,200 Shares of Cerus (NASDAQ:CERS) Stock

Mar -18

Source: defenseworld.net

Card image cap

Chrystal Jensen Sells 113,008 Shares of Cerus (NASDAQ:CERS) Stock

Mar -18

Source: defenseworld.net

Card image cap

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

Mar -16

Source: businesswire.com

Card image cap

Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference

Mar -09

Source: defenseworld.net

Card image cap

Cerus's Record 2025 Sets It Up For Another Leg Higher

Mar -05

Source: seekingalpha.com

Card image cap

Cerus Corporation (CERS) Q4 2025 Earnings Call Transcript

Mar -02

Source: seekingalpha.com

Card image cap

Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

Mar -02

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.00%)

6. Segments

Blood Safety

Expected Growth: 10.0%

Cerus Corporation's Blood Safety segment growth is driven by increasing adoption of Intercept Blood System, expansion into new geographies, and rising demand for pathogen-reduced blood components. Growing concerns over blood-borne diseases and regulatory support for blood safety measures also contribute to the 10.0% growth.

7. Detailed Products

INTERCEPT Blood System

A pathogen reduction technology designed to inactivate pathogens, viruses, and bacteria in blood components, ensuring a safer blood supply.

INTERCEPT Platelet System

A system that inactivates pathogens and viruses in platelet components, reducing the risk of transfusion-transmitted infections.

INTERCEPT Plasma System

A system that inactivates pathogens and viruses in plasma components, reducing the risk of transfusion-transmitted infections.

CONTRAST Optimization System

A software solution that helps optimize contrast media dosing in medical imaging procedures.

8. Cerus Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

Cerus Corporation's products are moderately susceptible to substitutes, as customers have some alternatives, but they are not easily replaceable.

Bargaining Power Of Customers

Cerus Corporation's customers have limited bargaining power due to the company's strong brand reputation and limited availability of alternatives.

Bargaining Power Of Suppliers

Cerus Corporation's suppliers have moderate bargaining power, as the company relies on a few key suppliers, but has some flexibility to switch to alternative suppliers.

Threat Of New Entrants

Cerus Corporation faces a high threat of new entrants, as the industry has low barriers to entry and new companies can easily enter the market.

Intensity Of Rivalry

Cerus Corporation operates in a highly competitive industry, with many established players and intense competition for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 60.97%
Debt Cost 8.66%
Equity Weight 39.03%
Equity Cost 10.49%
WACC 9.37%
Leverage 156.22%

11. Quality Control: Cerus Corporation passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
908 Devices

A-Score: 4.5/10

Value: 7.9

Growth: 2.9

Quality: 5.0

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Silk Road Medical

A-Score: 4.0/10

Value: 6.4

Growth: 5.6

Quality: 4.8

Yield: 0.0

Momentum: 6.0

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Avanos Medical

A-Score: 3.7/10

Value: 9.1

Growth: 2.3

Quality: 4.2

Yield: 0.0

Momentum: 1.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Cerus

A-Score: 3.5/10

Value: 5.2

Growth: 6.8

Quality: 3.4

Yield: 0.0

Momentum: 3.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
TELA Bio

A-Score: 3.1/10

Value: 7.8

Growth: 5.7

Quality: 3.6

Yield: 0.0

Momentum: 0.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Co-Diagnostics

A-Score: 2.5/10

Value: 8.0

Growth: 2.4

Quality: 4.1

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.03$

Current Price

2.03$

Potential

-0.00%

Expected Cash-Flows